Table 2.

Studies with Reported Treatment Terminations as a Result of Severe Infusion Reactions

Author	Year	Grade of IRs	Treatment	Patients with IRs (%)	Treatment Terminations among those with IRs (%)
Chemotherapy
Becouarn et al., [57]	2007	Grade 4	IRINOX	3%	100%
Desai et al., [58]	2005	Grade 3	Cyclosporine, irinotecan and 5-FU	6%	100%
Hsuen et al., [19]	2003	Grade 3	FOLFOX4	11%	100%
Ichikawa et al., [18]	2009	Grade 3-4	FOLFOX4 or Modified FOLFOX6	6%	50%
Kalofonos et al., [59]	2006	Grade 5	FOLFOX	1%	100%
Matsumoto et al., [56]	2008	Grade 3-4	Modified FOLFOX6	4%	60%
Seki et al., [60]	2009	Grade 3	5FU followed by FOLFOX4 or modified FOLFOX6	5%	100%
Shibata et al., [61]	2009	Grade 3	FOLFOX4	4%	100%
mAbs
Bachet et al., [39]	2007	Grade 3-4	Cetuximab	7%	100%
Bokemeyer et al., [53]	2009	Grade 3-4	Cetuximab + FOLFOX4	5%	88%
Cartwright et al., [28]	2008	Grade 3-4	Cetuximab + XELIRI	4%	100%
Foley et al., [40]	2010	Grade 3-4	Cetuximab with or without chemotherapy	8%	34%
George et al., [41]	2010	Grade 3	Cetuximab with or without chemotherapy	10%	100%
George et al., [41]	2010	Grade 4	Cetuximab With or without chemotherapy	7%	100%
Saltz et al., [34]	2004	Grade 3-4	Cetuximab	5%	67%
Schwartzberg et al., [14]	2008	Grade 3-4	Cetuximab	NA	82%
Schwartzberg et al., [14]	2008	Grade 3	Bevacizumab	NA	60%
Sobrero et al., [36]	2008	Grade 3-4	Cetuximab + Irinotecan	1%	100%

FOLFOX4, 5-FU/LV + oxaliplatin; mFOLFOX6, modified FOLFOX6; IRINOX, irinotecan + oxaliplatin; XELIRI, Xelox (capecitabine) + irinotecan.